Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GnRH antagonist in single-dose applications.

F Olivenne1, J M Ayoubi, R Fanchin

  • 1Department of Obstetrics and Gynecology and IVF Laboratory, A.Béclère Hopital, Clamart, France.

Human Reproduction Update
|September 6, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Canadian Surgery Forum: Abstracts of presentations to the Annual Meetings of the Canadian Association of Bariatric Physicians and Surgeons, Canadian Association of General Surgeons, Canadian Association of Thoracic Surgeons, Canadian Hepato-Pancreato-Biliary Association, Canadian Society of Surgical Oncology, Canadian Society of Colon and Rectal Surgeons, Vancouver, BC, Sept. 17-21, 2013.

Canadian journal of surgery. Journal canadien de chirurgie·2025
Same author

Fluorescence angiography with indocyanine green for low anterior resection in patients with rectal cancer: a prospective before and after study.

Techniques in coloproctology·2025
Same author

Towards the standardization of Hydra vulgaris bioassay for toxicity assessments of liquid samples.

Ecotoxicology and environmental safety·2024
Same author

Robotic-assisted excision of diffuse adenomyosis.

Facts, views & vision in ObGyn·2024
Same author

Horizons in Endometriosis: Proceedings of the Montreux Reproductive Summit, 14-15 July 2023.

Facts, views & vision in ObGyn·2024
Same author

Laparoscopic vaginal radical trachelectomy in the post-LACC era: step-by-step surgical procedure.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2022
Same journal

Clinical outcomes and euploidy rates of embryos derived from zygotes with nonpronuclear (0PN) and monopronuclear (1PN) in IVF or ICSI cycles: a systematic review and meta-analysis.

Human reproduction update·2026
Same journal

Sperm mitochondrial DNA copy number: a marker of male fertility and reproductive success.

Human reproduction update·2026
Same journal

Embryo-derived extracellular vesicles and their potential as biomarkers for embryo quality during IVF: a systematic review.

Human reproduction update·2026
Same journal

Endometriosis and ovarian cancer: epidemiological evidence, molecular insights, and clinical decision-making.

Human reproduction update·2026
Same journal

Maternal genetic variants associated with aneuploid conception: a narrative review.

Human reproduction update·2026
Same journal

Iron overload disorders in adults: a comprehensive review of gonadal function, reproductive, and sexual health.

Human reproduction update·2026
See all related articles

Single-dose gonadotrophin-releasing hormone (GnRH) antagonist, Cetrorelix, effectively prevents premature LH surges in IVF. This method offers shorter treatment, less medication, and fewer side effects compared to traditional protocols.

Area of Science:

  • Reproductive Endocrinology
  • In Vitro Fertilization (IVF) Protocols

Background:

  • Gonadotrophin-releasing hormone (GnRH) antagonists are utilized in ovarian stimulation to prevent premature luteinizing hormone (LH) surges.
  • Cetrorelix, a GnRH antagonist, has demonstrated efficacy in single-dose administration.

Purpose of the Study:

  • To evaluate the efficacy and safety of a single-dose GnRH antagonist (Cetrorelix) protocol in ovarian stimulation for IVF.
  • To compare Cetrorelix single-dose protocol with a GnRH agonist long protocol and its use in natural cycles.

Main Methods:

  • Administration of a single dose of Cetrorelix to prevent premature LH surges.
  • Comparison of IVF outcomes between Cetrorelix single-dose protocol and triptorelin (GnRH agonist) long protocol.
  • Assessment of Cetrorelix use in natural cycles with gonadotrophin support.

Related Experiment Videos

Main Results:

  • Single-dose Cetrorelix resulted in shorter treatment duration, reduced human menopausal gonadotrophin (HMG) requirement, and lower incidence of ovarian hyperstimulation syndrome (OHSS) compared to the GnRH agonist protocol.
  • Pregnancy rates were comparable between the Cetrorelix and GnRH agonist protocols.
  • In natural cycles, Cetrorelix reduced LH surges and cancellation rates with satisfactory preliminary pregnancy rates.
  • Cetrorelix exhibited excellent tolerance with mild, transient injection site reactions.

Conclusions:

  • Single-dose GnRH antagonist administration is an effective and well-tolerated option for ovarian stimulation in IVF.
  • This protocol offers advantages including reduced treatment burden and lower risk of OHSS.
  • Further studies are warranted to confirm its role as a first-choice IVF treatment in selected indications.